This paper describes work to develop a novel human antibody nasal spray as a prophylactic treatment against SARS-CoV-2. Formulations were developed at two protein concentrations and assessed for delivery using an Aptar VP3 nasal spray pump. Both formulations were shown to be suitable for nasal delivery in terms of pH, osmolality, and delivered droplet size; no evidence of protein agglomeration was observed as a result of spraying. Further studies are planned to investigate the stability of the developed products and to establish pharmacokinetics and pharmacodynamics.
Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery
This Might Also Be of Interest
Microbial integrity testing for preservative-free drug formulations
Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions
Interview with Guillaume Brouet on Aptar Pharma Services
Publications, Pharmaceutical, Innovation & Insights
Aptar Pharma provides guidance on FDA regulatory framework for OINDPs
Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions
Connected Medicine: Insights from Payers and Other Stakeholders
Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Product Solutions, Innovation & Insights
